| |
InSpectra™ StO2 Tissue Oxygenation Monitor
Noninvasive, Continuous, Real time and Direct Perfusion Status Monitoring.
Learn more about this technology during the sessions:
« Monitoring of tissue perfusion »
26 March Erasmus Room H: 8.30/ 10.00
Monitoring StO2 in traumatic shock
Jacques Duranteau (Le Kremlin-Bicêtre, France)
Monitoring StO2 in heart failure
Rüdger Kopp (Aachen, Germany)
Monitoring StO2 in sepsis
Jacques Creteur (Brussels, Belgium)
« Cardiovascular monitoring »
26 March Erasmus Room H : 13.30/ 15.30
StO2 monitoring
Nathan Shapiro (Boston, United States)
Or visit Hutchinson Technology Stand N. 36/ 37 Hall 11 |
Massive blood loss: Does rFVIIa help?
Trauma is frequently associated with massive bleeding and one third of trauma deaths are due to infractory hemorrhage. Dr Bertil Bouillon presented the results of a recent prospective, randomized, double-blinded, multi-center, placebo-controlled trial of rFVIIa (the CONTROL study) in patients with active hemorrhage due to trauma who had already received 4-8 units of RBCs. The trial was stopped for likely futility at interim analysis after inclusion of 573 patients and 30- and 90-day mortality and morbidity rates were indeed similar in treatment and placebo groups. However, rFVIIa-treated patients did have significantly lower transfusion requirements than placebo-treated patients both after blunt trauma and penetrating trauma. The placebo mortality rate was lower than expected (11% for blunt trauma and 13% for penetrating trauma) and Dr Bouillon suggested that the lack of a beneficial effect on survival or multiple organ failure outcomes may have been related to this fact and that further studies are needed to better determine which patients could best benefit from the blood-sparing properties of this agent.
Novel therapies for acute severe hypertension.
Marked blood pressure elevations and acute target-organ damage require immediate therapy as suggested by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). The pharmacologic agents used to treat acute severe hypertension are beta-adrenergic blockers, vasodilators, or both. This presentation reviewed novel pharmacologic approaches to treat vascular dysfunction and acute severe hypertension, and review recent advances and clincial trials including novel pharmacologic approaches.
|
|
|
LidCO, PiCCO, PRAM, NICOM, …. too many tools?
Dr Michael PINSKY
Measuring cardiac output is an essential part of hemodynamic monitoring in ICU patients. With increased concerns about the use of invasive techniques to measure cardiac output, notably the pulmonary artery catheter, the search has been on to discover less-invasive means of measurement and recent years has seen an influx of new methods, many making competing claims, leaving the clinician somewhat confused as to which is best. In a session dedicated to this issue, Dr Richard Beale first put this very clinically relevant topic into perspective by highlighting what is needed from a cardiac output monitor and offering a brief synopsis of how to compare the different techniques without an accepted “gold standard”. The invited faculty then presented some of the currently available systems. Dr Javier Belda pointed out that non-invasive techniques can also have limitations and complications, and finally Dr Michael Pinsky and Dr Jukka Takala summarized the indications for cardiac output monitoring and its clinical applications.
Keeping the right balance: Challenging current perceptions in volume replacement
Many solutions for perioperative volume replacement therapy contain non-physiological levels of sodium and chloride and are associated with metabolic acidosis and organ dysfunction. Using physiologically balanced crystalloids and colloids in a ‘total balanced volume replacement’ approach may reduce the risk of metabolic disturbance and provide better care for patients.1
On Wednesday, 25 March, Baxter welcomed delegates to ‘Keeping the right balance: Challenging current perceptions in volume replacement’, a symposium that featured three leading European experts discussing the optimisation of volume replacement therapy for improved clinical outcomes.
Professor Joachim Boldt chaired the event and presented an overview of ‘total balanced volume replacement’ and its implications for clinical practice. New British guidelines on intravenous fluid therapy recommend using balanced fluids for volume replacement. Professor Dileep Lobo explained the rationale for the guidelines and discussed the importance of distinguishing between fluid replacement and fluid maintenance in clinical practice. In his presentation ‘Back to basics: the physiological impact of volume replacement therapy on the microcirculation’, Professor Can Ince highlighted the importance of the microcirculation in organ function and how a greater understanding of this system may help to improve treatment for hypovolaemia.
Boldt J. The balanced concept of fluid resuscitation. Br J Anaesth 2007;99:312–5. |
|
|
Welcome to the Baxter stand
We would be pleased to welcome you at the Baxter exhibition booth in Hall 7
(booth no. 07.029-07.032).
-
Join us for a coffee and a freshly baked Belgian waffle.
-
Take part in our interactive quiz about nutrition facts.
-
Learn about Baxter’s volume replacement therapy.
-
Do you know your current MRSA (Methicillin resistant Staphylococcus aureus) status?
Get your free MRSA status check at the Baxter booth.
It’s an easy 2 minutes nasal swab. You will get an accurate result from DNA based testing. You will be assigned a number to make the test completely anonymous. Give enhanced patient care by combining good aseptic technique and Baxter’s novel technology.
Looking forward to seeing you at the Baxter booth. |
|
|
|
.gif)
